Cybin Inc. (CYBN)
After hours:
| Previous Close | 0.2892 |
| Open | 0.2756 |
| Bid | 0.2700 x 900 |
| Ask | 0.2720 x 1200 |
| Day's Range | 0.2680 - 0.2780 |
| 52 Week Range | 0.2660 - 0.7380 |
| Volume | |
| Avg. Volume | 4,185,706 |
| Market Cap | 206.484M |
| Beta (5Y Monthly) | 1.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ZacksDown -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround
Cybin Inc. (CYBN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Business WireCybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development
TORONTO, June 11, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, is pleased to announce that Dr. Atul R. Mahableshwarkar M.D., DLFAPA, has joined the Company as Senior Vice President, Clinical Development. Dr. Mahableshwarkar will lead the development of the CYB003 program, Cybin’s proprie
Business WireCybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024
TORONTO, May 29, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that Amir Inamdar, MBBS, DNB (Psych), MFPM, Cybin’s Chief Medical Officer, and Ellen James, Ph.D., Cybin’s Director, Clinical Development, will participate at the Interdisciplinary Conference on Psychedelic Res
